Lead Product(s): HFB30132A
Therapeutic Area: Infections and Infectious Diseases Product Name: HFB30132A
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: HiFiBiO Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 14, 2020
Partnership with ABL Bio supports HiFiBiO Therapeutics' rapid clinical advancement of its SARS-CoV-2 neutralizing antibody, HFB30132A, for the treatment of COVID-19 patients.